Reproducible diagnosis of chronic lymphocytic leukemia by flow
cytometry: An European Research Initiative on CLL (ERIC) &
European Society for Clinical Cell Analysis (ESCCA)
Harmonisation project

J 2018

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

RAWSTRON, A.C.; K.A. KREUZER; A. SOOSAPILLA; M. SPACEK; Olga STEHLÍKOVÁ et al.

Základní údaje

Originální název

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

Autoři

Vydání

Cytometry Part B ( Clinical cytometry), HOBOKEN, WILEY-BLACKWELL, 2018, 1552-4949

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30109 Pathology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.938

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14740/18:00102937

Organizační jednotka

Středoevropský technologický institut

Klíčová slova anglicky

chronic lymphocytic leukemia; flow cytometry; diagnosis

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 13. 3. 2019 16:49, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of this project was to identify reproducible criteria and consensus on markers recommended for the diagnosis of CLL. ERIC/ESCCA members classified 14 of 35 potential markers as required or recommended for CLL diagnosis, consensus being defined as >75% and >50% agreement, respectively. An approach to validate required markers using normal peripheral blood was developed. Responses were received from 150 participants with a diagnostic workload >20 CLL cases per week in 23/150 (15%), 5-20 in 82/150 (55%), and <5 cases per week in 45/150 (30%). The consensus for required diagnostic markers included: CD19, CD5, CD20, CD23, Kappa, and Lambda. Recommended markers potentially useful for differential diagnosis were: CD43, CD79b, CD81, CD200, CD10, and ROR1. Reproducible criteria for component reagents were assessed retrospectively in 14,643 cases from 13 different centers and showed >97% concordance with current approaches. A pilot study to validate staining quality was completed in 11 centers. Markers considered as required for the diagnosis of CLL by the participants in this study (CD19, CD5, CD20, CD23, Kappa, and Lambda) are consistent with current diagnostic criteria and practice. Importantly, a reproducible approach to validate and apply these markers in individual laboratories has been identified. Finally, a consensus recommended panel of markers to refine diagnosis in borderline cases (CD43, CD79b, CD81, CD200, CD10, and ROR1) has been defined and will be prospectively evaluated. (c) 2017 International Clinical Cytometry Society

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

NV15-30015A, projekt VaV

Název: Analýza klonální heterogenity chronické lymfocytární leukemie pomoci sekvenování nové generace genu pro B-buněčný receptor. Národní studie.

Citovat

RAWSTRON, A.C.; K.A. KREUZER; A. SOOSAPILLA; M. SPACEK; Olga STEHLÍKOVÁ; P. GAMBELL; N. MCIVER-BROWN; N. VILLAMOR; K. PSARRA; M. ARROZ; R. MILANI; J. DE LA SERNA; M.T. CEDENA; O. JAKSIC; J. NOMDEDEU; C. MORENO; G.M. RIGOLIN; A. CUNEO; P. JOHANSEN; H.E. JOHNSEN; R. ROSENQUIST; C.U. NIEMANN; W. KERN; D. WESTERMAN; M. TRNENY; S. MULLIGAN; Michael DOUBEK; Šárka POSPÍŠILOVÁ; P. HILLMEN; D. OSCIER; M. HALLEK; P. GHIA a E. MONTSERRAT. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry Part B ( Clinical cytometry). HOBOKEN: WILEY-BLACKWELL, 2018, roč. 94, č. 1, s. 121-128. ISSN 1552-4949. Dostupné z: https://doi.org/10.1002/cyto.b.21595.

@article{1419884,
   author = {Rawstron, A.C. and Kreuzer, K.A. and Soosapilla, A. and Spacek, M. and Stehlíková, Olga and Gambell, P. and McIverandBrown, N. and Villamor, N. and Psarra, K. and Arroz, M. and Milani, R. and de la Serna, J. and Cedena, M.T. and Jaksic, O. and Nomdedeu, J. and Moreno, C. and Rigolin, G.M. and Cuneo, A. and Johansen, P. and Johnsen, H.E. and Rosenquist, R. and Niemann, C.U. and Kern, W. and Westerman, D. and Trneny, M. and Mulligan, S. and Doubek, Michael and Pospíšilová, Šárka and Hillmen, P. and Oscier, D. and Hallek, M. and Ghia, P. and Montserrat, E.},
   article_location = {HOBOKEN},
   article_number = {1},
   doi = {https://doi.org/10.1002/cyto.b.21595},
   keywords = {chronic lymphocytic leukemia; flow cytometry; diagnosis},
   language = {eng},
   issn = {1552-4949},
   journal = {Cytometry Part B ( Clinical cytometry)},
   title = {Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project},
   url = {https://onlinelibrary.wiley.com/doi/pdf/10.1002/cyto.b.21595},
   volume = {94},
   year = {2018}
}

TY  - JOUR
ID  - 1419884
AU  - Rawstron, A.C. - Kreuzer, K.A. - Soosapilla, A. - Spacek, M. - Stehlíková, Olga - Gambell, P. - McIver-Brown, N. - Villamor, N. - Psarra, K. - Arroz, M. - Milani, R. - de la Serna, J. - Cedena, M.T. - Jaksic, O. - Nomdedeu, J. - Moreno, C. - Rigolin, G.M. - Cuneo, A. - Johansen, P. - Johnsen, H.E. - Rosenquist, R. - Niemann, C.U. - Kern, W. - Westerman, D. - Trneny, M. - Mulligan, S. - Doubek, Michael - Pospíšilová, Šárka - Hillmen, P. - Oscier, D. - Hallek, M. - Ghia, P. - Montserrat, E.
PY  - 2018
TI  - Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project
JF  - Cytometry Part B ( Clinical cytometry)
VL  - 94
IS  - 1
SP  - 121-128
EP  - 121-128
PB  - WILEY-BLACKWELL
SN  - 15524949
KW  - chronic lymphocytic leukemia
KW  - flow cytometry
KW  - diagnosis
UR  - https://onlinelibrary.wiley.com/doi/pdf/10.1002/cyto.b.21595
N2  - The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of this project was to identify reproducible criteria and consensus on markers recommended for the diagnosis of CLL. ERIC/ESCCA members classified 14 of 35 potential markers as required or recommended for CLL diagnosis, consensus being defined as >75% and >50% agreement, respectively. An approach to validate required markers using normal peripheral blood was developed. Responses were received from 150 participants with a diagnostic workload >20 CLL cases per week in 23/150 (15%), 5-20 in 82/150 (55%), and <5 cases per week in 45/150 (30%). The consensus for required diagnostic markers included: CD19, CD5, CD20, CD23, Kappa, and Lambda. Recommended markers potentially useful for differential diagnosis were: CD43, CD79b, CD81, CD200, CD10, and ROR1. Reproducible criteria for component reagents were assessed retrospectively in 14,643 cases from 13 different centers and showed >97% concordance with current approaches. A pilot study to validate staining quality was completed in 11 centers. Markers considered as required for the diagnosis of CLL by the participants in this study (CD19, CD5, CD20, CD23, Kappa, and Lambda) are consistent with current diagnostic criteria and practice. Importantly, a reproducible approach to validate and apply these markers in individual laboratories has been identified. Finally, a consensus recommended panel of markers to refine diagnosis in borderline cases (CD43, CD79b, CD81, CD200, CD10, and ROR1) has been defined and will be prospectively evaluated. (c) 2017 International Clinical Cytometry Society
ER  -

RAWSTRON, A.C.; K.A. KREUZER; A. SOOSAPILLA; M. SPACEK; Olga STEHLÍKOVÁ; P. GAMBELL; N. MCIVER-BROWN; N. VILLAMOR; K. PSARRA; M. ARROZ; R. MILANI; J. DE LA SERNA; M.T. CEDENA; O. JAKSIC; J. NOMDEDEU; C. MORENO; G.M. RIGOLIN; A. CUNEO; P. JOHANSEN; H.E. JOHNSEN; R. ROSENQUIST; C.U. NIEMANN; W. KERN; D. WESTERMAN; M. TRNENY; S. MULLIGAN; Michael DOUBEK; Šárka POSPÍŠILOVÁ; P. HILLMEN; D. OSCIER; M. HALLEK; P. GHIA a E. MONTSERRAT. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) \&{}amp; European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. \textit{Cytometry Part B ( Clinical cytometry)}. HOBOKEN: WILEY-BLACKWELL, 2018, roč.~94, č.~1, s.~121-128. ISSN~1552-4949. Dostupné z: https://doi.org/10.1002/cyto.b.21595.

Přehled o publikaci